UCB.BR
Price:
$178.15
Market Cap:
$33.80B
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treati...[Read more]
Industry
Biotechnology
IPO Date
2000-01-04
Stock Exchange
EURONEXT
Ticker
UCB.BR
According to UCB SA’s latest financial reports and current stock price. The company's current PE Ratio is 144.84. This represents a change of 67.28% compared to the average of 86.58 of the last 4 quarters.
The mean historical PE Ratio of UCB SA over the last ten years is 35.45. The current 144.84 PE Ratio has changed 40.76% with respect to the historical average. Over the past ten years (40 quarters), UCB.BR's PE Ratio was at its highest in in the December 2022 quarter at 183.51. The PE Ratio was at its lowest in in the December 2016 quarter at 0.
Average
35.45
Median
21.94
Minimum
16.72
Maximum
104.67
Discovering the peaks and valleys of UCB SA PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 86.17%
Maximum Annual PE Ratio = 104.67
Minimum Annual Increase = -63.56%
Minimum Annual PE Ratio = 16.72
Year | PE Ratio | Change |
---|---|---|
2023 | 43.79 | 31.23% |
2022 | 33.37 | 86.17% |
2021 | 17.92 | -17.84% |
2020 | 21.82 | 30.17% |
2019 | 16.76 | -0.23% |
2018 | 16.80 | 0.45% |
2017 | 16.72 | -24.21% |
2016 | 22.06 | -63.56% |
2015 | 60.56 | -42.14% |
2014 | 104.67 | -12.97% |
The current PE Ratio of UCB SA (UCB.BR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
31.69
5-year avg
26.73
10-year avg
35.45
UCB SA’s PE Ratio is greater than Solvay SA (2.17), greater than KBC Group NV (9.32), greater than Groupe Bruxelles Lambert SA (2.90), greater than ageas SA/NV (12.85), greater than Ackermans & Van Haaren NV (14.30),
Company | PE Ratio | Market cap |
---|---|---|
2.17 | $3.94B | |
9.32 | $27.56B | |
2.90 | $8.53B | |
12.85 | $8.83B | |
14.30 | $6.13B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like UCB SA using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like UCB SA or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is UCB SA's PE Ratio?
How is the PE Ratio calculated for UCB SA (UCB.BR)?
What is the highest PE Ratio for UCB SA (UCB.BR)?
What is the 3-year average PE Ratio for UCB SA (UCB.BR)?
What is the 5-year average PE Ratio for UCB SA (UCB.BR)?
How does the current PE Ratio for UCB SA (UCB.BR) compare to its historical average?